Slu-pp-332 Capsules
Price range: 59,00 € through 95,00 €
Slu-pp-332 Capsules
Description
SLU-PP-332 is a synthetic small-molecule pan-ERR agonist studied for its ability to activate the three estrogen-related receptors (ERRα, ERRβ, ERRγ), master regulators of cellular energy metabolism and mitochondrial biogenesis. It is investigated in preclinical models for its capacity to mimic exercise-induced metabolic adaptations without physical activity.
In experimental models, SLU-PP-332 has been observed to increase mitochondrial density, enhance fatty acid oxidation, and improve endurance capacity through upregulation of oxidative phosphorylation genes and PGC-1α-related transcriptional programs. Research animals have shown improved running performance, reduced adipose tissue accumulation, and resistance to diet-induced obesity following oral administration.
Beyond metabolic effects, SLU-PP-332 has been evaluated for its influence on thermogenesis, insulin sensitivity, and cardiac stress resistance, with reported improvements in glucose tolerance and lipid profiles in rodent studies.
Formulated as a pre-dosed oral capsule, SLU-PP-332 offers convenient, reproducible dosing for laboratory research, with consistent capsule-to-capsule strength under standardized storage.
Clinical Status:
SLU-PP-332 is a research compound evaluated exclusively in preclinical rodent and in vitro studies for metabolic, endurance, and mitochondrial endpoints. It is not approved for medical use and remains restricted to experimental and laboratory research.
Evidence type:
Human RCT ☐ | Observational ☐ | Animal ✔ | In vitro ✔ | Regulatory ☐
Mechanism of Action
Slu-PP-332 acts as a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ), a family of orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, and fatty-acid metabolism. By stabilising the active conformation of these receptors, the compound is reported in preclinical work to enhance PGC-1α-linked transcriptional programmes, increasing mitochondrial density and lipid oxidation. As a small-molecule taken orally, the swallowed capsule is studied for endurance-related and exercise-mimetic effects in laboratory models.
Benefits
The following research-reported properties summarise areas where Slu-PP-332 has been examined in preclinical and experimental settings. These observations are drawn primarily from rodent and cell-based studies and are presented for research context only; they describe investigational findings rather than therapeutic outcomes or approved indications in humans.
- Mitochondrial biogenesis: As an ERR pan-agonist, Slu-PP-332 has been reported to activate transcriptional programmes that drive the formation of new mitochondria. In animal studies this has been associated with increased mitochondrial density in metabolically active tissues such as skeletal muscle, a core focus of the compound’s research profile.
- Exercise-mimetic activity: A central theme in the literature is that Slu-PP-332 reproduces several molecular signatures of physical exercise without the exercise itself. Researchers have described upregulation of endurance-associated genes and improved oxidative capacity in treated animals, leading to the compound being characterised as an exercise mimetic in experimental work.
- Endurance and oxidative capacity: Preclinical models have examined running performance and fatigue resistance, with reports of enhanced endurance in treated rodents. These effects are attributed to the compound’s activation of oxidative phosphorylation and fatty-acid metabolism pathways downstream of ERR signalling.
- Lipid and energy metabolism: Studies describe increased fatty-acid oxidation and shifts in whole-body energy expenditure. In diet-induced obesity models, researchers have reported reduced fat accumulation and improved metabolic parameters, positioning the compound as a tool for studying metabolic regulation.
- PGC-1α pathway engagement: Much of the reported activity converges on the PGC-1α co-activator network, a master regulator of energy metabolism. By reinforcing this pathway through ERR activation, Slu-PP-332 is used in research to probe how mitochondrial gene expression is controlled.
- Skeletal-muscle research: Beyond endurance endpoints, the compound has been used to investigate muscle fibre-type composition and the adaptive responses of muscle tissue to enhanced oxidative signalling in controlled experiments, with reports of a shift toward more oxidative, fatigue-resistant fibre characteristics.
- Thermogenesis and metabolic flexibility: Because ERR activation engages programmes that govern how cells generate and expend energy, researchers have also examined Slu-PP-332 in the context of thermogenic signalling and metabolic flexibility, studying how treated tissues switch between fuel sources under different conditions.
- Convenient oral research format: Supplied as pre-measured 300 mcg capsules, this presentation supports consistent, repeatable dosing in research protocols. The pre-dosed oral format removes additional handling steps and simplifies study design wherever an oral route of exposure is preferred, allowing investigators to standardise exposure across study arms.
Each of these points reflects findings from the experimental literature rather than approved indications. Slu-PP-332 capsules are intended strictly for laboratory and research purposes and are not for human or veterinary use.
Research Data
| Research Area | Model / Setting | Reported Observation |
|---|---|---|
| Mitochondrial biogenesis | Rodent skeletal muscle | Increased mitochondrial density via ERR activation |
| Endurance capacity | Treadmill running models | Enhanced running distance and fatigue resistance reported |
| Energy metabolism | Diet-induced obesity mice | Reduced fat accumulation and increased energy expenditure |
| Lipid oxidation | Cell and animal studies | Upregulated fatty-acid oxidation pathways |
| Receptor pharmacology | In vitro ERR assays | Pan-agonist activity across ERRα, ERRβ and ERRγ |
Data above is summarised from preclinical and in-vitro literature and is provided for research orientation only. It does not constitute clinical evidence of efficacy in humans.
Stack Suggestions
In research protocols, Slu-PP-332 is sometimes studied alongside other compounds investigated for metabolic and endurance endpoints, evaluated for complementary effects in controlled settings:
- Slu-PP-332 → 5-Amino-1MQ — paired in metabolic and body-composition models.
- Slu-PP-332 → MOTS-c — examined in mitochondrial and exercise-mimetic studies.
- Slu-PP-332 → SR9009 — explored in endurance and energy-metabolism research.
⚠ Combinations are listed for research context only and do not imply safety or efficacy in humans. All pairings should follow validated protocols with appropriate controls.
Capsule Dosage Chart
| Slu-pp-332 Capsules – 300 mcg | |
| Strength | 300 mcg (0.3 mg) per capsule |
| Bottle sizes | 30 or 60 capsules |
| Standard serving | 1 capsule once daily |
| Total content | 9 mg (30 capsules) / 18 mg (60 capsules) |
Dosage & Protocols Variations
Slu-PP-332 Capsules supply 300 mcg per capsule (bottles of 30 or 60), dosed in whole-capsule increments and taken orally with water.
Standard Research Protocol
- Dose: 300 mcg (1 capsule)
- Duration: 4 – 8 weeks
- Frequency: 1 capsule once daily, with water
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline protocol for metabolic and mitochondrial research models.
Therapeutic Research Protocol
- Dose: 300 – 600 mcg (1 – 2 capsules)
- Duration: 6 – 10 weeks
- Frequency: Once daily, preferably before physical-activity windows
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Used in research targeting endurance, fat oxidation, and ERR pathway activation.
Biohacker Protocol (experimental)
- Dose: 300 mcg (1 capsule)
- Duration: 8 – 12 weeks
- Frequency: 1 capsule daily, continuous low-dose exposure
- Cycle Interval: 4 weeks off after each cycle
- Goal / Description: Explored for sustained mitochondrial biogenesis and metabolic adaptation in long-term models.
Possible Side Effects
Slu-PP-332 is a relatively new research compound, and its safety profile has been characterised only in preclinical settings. In the rodent studies reported to date it has generally been described as tolerated across the dose ranges examined, but comprehensive controlled human safety data do not exist, so conclusions about tolerability in people remain unconfirmed.
Because the compound acts on receptors central to energy metabolism, researchers note that its effects on metabolic and cardiovascular parameters are still being investigated. As with any investigational substance, unknown or idiosyncratic responses cannot be excluded, and the long-term safety of Slu-PP-332 has not been formally established.
This product is intended strictly for laboratory and research use. It is not a medicine, is not intended for human or veterinary consumption, and must be handled only by qualified personnel following appropriate safety practices.
Product Attributes
- Compound class: Synthetic small-molecule ERR (estrogen-related receptor) agonist
- Receptor targets: Pan-agonist of ERRα, ERRβ and ERRγ
- CAS #: Not publicly assigned for this research compound
- Molecular form: Small-molecule organic compound (non-peptide)
- Format: Oral capsule, 300 mcg per capsule
- Status: For laboratory research use only
Scientific References
- Billon C, Sitaula S, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023.
- Billon C, Schoepke E, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024.
- Billon C, Appourchaux K, et al. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity. J Pharmacol Exp Ther. 2026.
- Audet-Walsh É, Giguère V. The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta Pharmacol Sin. 2015.
References are provided for research orientation only and describe preclinical or experimental work.
Included In The Box
Every order arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage. Inside, you will find everything needed for your full research protocol:
- 1× Sealed bottle of capsules, tamper-evident and ready to use — no preparation required
- Desiccant pack included to keep the capsules dry and stable
- Internal Stabilizing Foam Insert to protect the bottle during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the bottle in a cool, dry place away from direct light, and keep it tightly closed between uses. No refrigeration is required.
Avoid exposure to heat, humidity, and repeated temperature changes to preserve potency. Keep the desiccant pack inside the bottle.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
